Project Grant R01DK132019

Award Date 5/2/24
Completion Date 4/30/28
Dollars Obligated $481K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of tau phosphorylation in diabetic peripheral neuropathy. The award, totaling $207,960, will fund a research project at the University of Texas MD Anderson Cancer Center to identify increases in tau phosphorylation and insulin signaling dysregulation in the sciatic nerve of a diabetic neuropathy model....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to generate human induced pluripotent stem cell (iPSC) models of type 2 diabetic cardiomyopathy (T2DCM) and assess the metabolic mechanisms and protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors. The total award is $511,864 with a project period from Sep 6, 2024 to Mar 31, 2026. The research will be...
This Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support the development of novel angiotensin AT2 receptor inhibitors for the treatment of neuropathic pain. The $818,360 award to the University of Southern California will fund research to optimize lead compounds showing improved potency, efficacy, and safety profiles compared...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $5,666,172 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University (NYU) to conduct research on targeting Schwann cell dysfunction and repair signaling in chemotherapy-induced painful peripheral neuropathy (CIPPN). The research aims to study the role of the peroxisome proliferator activated receptor gamma (PPARG) and low-density lipoprotein receptor related protein 1 (LRP1)...
This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...
This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
The University of California, San Diego (UCSD) was awarded a $434,500 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The funding will support research to investigate the regulation of Schwann cell mitochondria homeostasis and its role in painful peripheral neuropathy. Specifically, the project aims to examine how the low-density lipoprotein...
This Project Grant award of $2,068,842 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify how pain influences the activity of prefrontal cortical dynorphin neurons and their role in modulating nociception and maladaptive affective behaviors. The research aims to dissect the mechanisms by which dynorphin neurons and release of dynorphin neuropeptides or fast neurotransmitters...
This $2,370,000 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop advanced human pluripotent stem cell (HPSC) tools to create comprehensive, region-specific models for studying pain circuitry. The award to Trustees of Tufts College (Tufts University) supports three main objectives: 1) Developing scalable methods to generate region-specific sensory neurons and...

ANGIOTENSIN SIGNALING UNDERLIES MYELOID AND SENSORY DISRUPTION IN DIABETES - PROJECT SUMMARY/ABSTRACT NEUROPATHY ASSOCIATED WITH TYPE 2 DIABETES (T2D) IS FREQUENTLY ASSOCIATED WITH PAIN AND SENSORY LOSS. OUR INCOMPLETE MECHANISTIC UNDERSTANDING OF THE PATHOPHYSIOLOGY OF NERVE INJURY IN T2D HINDERS OUR ABILITY TO DEVELOP MORE EFFECTIVE DRUGS AND THERAPEUTIC STRATEGIES. GIVEN THE EMERGING ROLE OF MYELOID CELLS, PARTICULARLY MACROPHAGES, ACROSS VARIOUS TYPES OF NEUROPATHY, THEIR APPARENT INVOLVEMENT IN DIVERSE FORMS OF NERVE INJURY PAIN AND THE KNOWN INCREASE IN PRODUCTION OF THE PEPTIDE HORMONE ANGIOTENSIN II (ANG II) IN DIABETES, WE POSIT THAT ELEVATED ANG II IN T2D PRECIPITATES NEUROPATHY, PAIN AND SENSORY LOSS BY DISRUPTING MYELOID CELL DEVELOPMENT AND PHENOTYPE. HOWEVER, MANY KNOWLEDGE GAPS PERSIST. OUR PRELIMINARY STUDIES INDICATE THAT CIRCULATING IMMATURE MYELOID CELL NUMBERS ARE INCREASED IN DIET-INDUCED AND GENETIC MODELS OF T2D, A CHANGE ALSO ASSOCIATED WITH ELEVATED LEVELS OF ANG II IN LYMPHOID TISSUES. FURTHERMORE, THE SENSORY GAIN OBSERVED IN DIET-INDUCED T2D IS REVERSIBLE BY INHIBITORS OF ANG II PRODUCTION. THE OVERALL GOAL OF THIS PROJECT IS TO IDENTIFY HOW ANG II DISRUPTS MYELOID CELLS IN T2D, CULMINATING IN NEUROPATHY, SENSORY LOSS AND PAIN. THE FIRST SPECIFIC AIM WILL ASSESS THE EXTENT OF ALTERATIONS TO MYELOPOIESIS ACROSS THE PROGRESSION FROM METABOLIC SYNDROME TO EARLY STAGE T2D TO LATE-STAGE T2D, AND WHETHER INCREASES IN ANG II ARE CAUSALLY RELATED. THE SECOND SPECIFIC AIM WILL DETERMINE THE DEGREE TO WHICH T2D MODIFIES TISSUE-RESIDENT MYELOID CELL FUNCTION IN WAYS THAT PROMOTE SENSORY DYSFUNCTION. FINALLY, THE THIRD SPECIFIC AIM WILL DETERMINE IF OPPOSING T2D-RELATED CHANGES IN ANGIOTENSIN SIGNALING CAN NORMALIZE PATHOLOGICAL CHANGES TO MYELOID CELLS, THEREBY REDUCING SENSORY DYSFUNCTION. OUR MULTIDISCIPLINARY APPROACH INVOLVES PRECLINICAL T2D MODELS, REFLEXIVE AND VOLUNTARY PAIN-BEHAVIORAL STUDIES, IMMUNOHISTOCHEMISTRY, IN VITRO LIVE CELL FUNCTIONAL IMAGING, SINGLE CELL RNA AND ATAC-SEQUENCING AND TRANSCRIPTOMIC ANALYSIS OF HUMAN SKIN BIOPSIES. OUR PROJECT WILL UNAMBIGUOUSLY DISSECT THE NATURE OF ANG II-BASED MYELOID CELL DISRUPTION TO DETERMINE THE ROLE OF THE RENIN-ANGIOTENSIN SYSTEM AND MACROPHAGE-DRIVEN INFLAMMATION IN THE DEVELOPMENT OF PERIPHERAL NEUROPATHY AND CHRONIC PAIN IN T2D. ELUCIDATING THE MECHANISTIC UNDERPINNINGS OF SENSORY LOSS AND PAIN IN T2D NEUROPATHY IS CRITICAL TO ADVANCING OUR UNDERSTANDING OF THE UNDERLYING MECHANISM(S), AS WELL AS RAPID TRANSLATION INTO DEVELOPMENT OF NEW- GENERATION, EFFICACIOUS, NON-OPIOID ANALGESICS THAT TARGET SUCH NEURO-IMMUNE CROSSTALK.

Posted 5/2/24, 12:00 AM